Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 4, 2008 - Issue 1
Submit an article Journal homepage
55
Views
39
CrossRef citations to date
0
Altmetric
Expert Opinion

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features

Angelo Antonini1 Parkinson Institute, Istituti Clinici di PerfezionamentoMilan, ItalyCorrespondence[email protected]
,
Giovanni Abbruzzese2 Movement Disorder Unit, Neurology, University of GenoaGenoa, Italy
,
Paolo Barone3 Dipartimento di Scienze Neurologiche, Università di Napoli Federico IINaples, Italy
,
Ubaldo Bonuccelli4 University of Pisa, Department of NeurosciencePisa, Italy
,
Leonardo Lopiano5 Department of Neuroscience, University of TurinTurin, Italy
,
Marco Onofrj6 Department of Oncology and Neuroscience, University G D’Annunzio, G D’Annunzio Foundation CESIChieti-Pescara, Italy
,
Mario Zappia7 Department of Neurosciences, University of CataniaCatanzaro, Italy
&
Aldo Quattrone8 Institute of Neurology, University “Magna Græcia”Catanzaro, Italy
 show all
Pages 1-9 | Published online: 08 Feb 2008

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Livia Dézsi & László Vécsei. (2014) Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opinion on Drug Metabolism & Toxicology 10:3, pages 409-424.
Read now
Daniel D Truong. (2009) Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease. Clinical Interventions in Aging 4, pages 109-113.
Read now
Roger M Pinder. (2008) Editorial. Neuropsychiatric Disease and Treatment 4:1, pages i-ii.
Read now

Articles from other publishers (36)

Joana Rebouta, M. Luísa Dória, Filipa Campos, Francisca Araújo & Ana I. Loureiro. (2023) DESI-MSI-based technique to unravel spatial distribution of COMT inhibitor Tolcapone. International Journal of Pharmaceutics 633, pages 122607.
Crossref
Ana M. Gonçalves, Ângela Sousa, Augusto Q. Pedro, Maria J. Romão, João A. Queiroz, Eugénia Gallardo & Luís A. Passarinha. (2022) Advances in Membrane-Bound Catechol-O-Methyltransferase Stability Achieved Using a New Ionic Liquid-Based Storage Formulation. International Journal of Molecular Sciences 23:13, pages 7264.
Crossref
Joanna Kaminska, Piotr Soczewka, Weronika Rzepnikowska & Teresa Zoladek. (2022) Yeast as a Model to Find New Drugs and Drug Targets for VPS13-Dependent Neurodegenerative Diseases. International Journal of Molecular Sciences 23:9, pages 5106.
Crossref
Pedro Cruz-Vicente, Ana M. Gonçalves, Octávio Ferreira, João A. Queiroz, Samuel Silvestre, Luís A. Passarinha & Eugenia Gallardo. (2021) Discovery of Small Molecules as Membrane-Bound Catechol-O-methyltransferase Inhibitors with Interest in Parkinson’s Disease: Pharmacophore Modeling, Molecular Docking and In Vitro Experimental Validation Studies. Pharmaceuticals 15:1, pages 51.
Crossref
Tien Tan Bui & Hee-Kwon Kim. (2021) Facile one-pot synthesis of ketones from primary alcohols under mild conditions. New Journal of Chemistry 45:30, pages 13323-13328.
Crossref
Mohammad Al Majali, Michael Sunnaa & Pratap Chand. (2021) Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease. Journal of Geriatric Psychiatry and Neurology 34:4, pages 263-273.
Crossref
Violina Kakoty, Sarathlal K C, Sunil Kumar Dubey, Chih Hao Yang, Prashant Kesharwani & Rajeev Taliyan. (2021) The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. Neuroscience Letters 753, pages 135865.
Crossref
Kenneth Wu, Khoi Q. HuynhIris Lu, Moses Moustakim, Haibin MiaoClinton Yu, Matthew J. Haeusgen, Benjamin D. Hopkins, Lan Huang, Ning ZhengRoberto SanchezRobert J. DeVita & Zhen-Qiang Pan. (2021) Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential. Proceedings of the National Academy of Sciences 118:8.
Crossref
Degirmenci Husnu, Bakirci Eftal Murat & Hamur Hikmet. (2020) Cardiac Effects of Parkinson’s Disease. Open Journal of Parkinson's Disease and Treatment, pages 006-007.
Crossref
Massimo Russo, Luca Gentile, Antonio Toscano, M’Hammed Aguennouz, Giuseppe Vita & Anna Mazzeo. (2020) Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects. Brain Sciences 10:12, pages 952.
Crossref
Piotr Soczewka, Krzysztof Flis, Déborah Tribouillard-Tanvier, Jean-Paul di Rago, Cláudia N. Santos, Regina Menezes, Joanna Kaminska & Teresa Zoladek. (2020) Flavonoids as Potential Drugs for VPS13-Dependent Rare Neurodegenerative Diseases. Genes 11:7, pages 828.
Crossref
Nirosen Vijiaratnam & Thomas Foltynie. (2020) Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease. Drugs 80:8, pages 775-796.
Crossref
Martin Klietz, Stephan Greten, Florian Wegner & Günter U. Höglinger. (2019) Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients. Drugs & Aging 36:6, pages 511-530.
Crossref
Nikola Minovski, Melek Türker Saçan, Elif Merve Eminoğlu, Safiye Sağ Erdem & Marjana Novič. (2019) Revisiting fish toxicity of active pharmaceutical ingredients: Mechanistic insights from integrated ligand-/structure-based assessments on acetylcholinesterase. Ecotoxicology and Environmental Safety 170, pages 548-558.
Crossref
Vaibhav Walia, Ashish Gakkhar & Munish Garg. 2019. Handbook of Research on Critical Examinations of Neurodegenerative Disorders. Handbook of Research on Critical Examinations of Neurodegenerative Disorders 252 273 .
Ghobad Mohammadi, Khodabakhsh Rashidi, Majid Mahmoudi, Hector C. Goicoechea & Ali R. Jalalvand. (2018) Exploiting second-order advantage from mathematically modeled voltammetric data for simultaneous determination of multiple antiparkinson agents in the presence of uncalibrated interference. Journal of the Taiwan Institute of Chemical Engineers 88, pages 49-61.
Crossref
Irene Katsaiti & John Nixon. (2018) Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson’s Disease Patients? A Systematic Review. Journal of Parkinson's Disease 8:2, pages 217-231.
Crossref
Aniket Magarkar, Petteri Parkkila, Tapani Viitala, Tatu Lajunen, Edouard Mobarak, Giuseppe Licari, Oana Cramariuc, Eric Vauthey, Tomasz Róg & Alex Bunker. (2018) Membrane bound COMT isoform is an interfacial enzyme: general mechanism and new drug design paradigm. Chemical Communications 54:28, pages 3440-3443.
Crossref
Panchanan Maiti, Jayeeta Manna & Gary L. Dunbar. (2017) Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. Translational Neurodegeneration 6:1.
Crossref
Omar Abdulhameed Almazroo, Mohammad Kowser Miah & Raman Venkataramanan. (2017) Drug Metabolism in the Liver. Clinics in Liver Disease 21:1, pages 1-20.
Crossref
Keng Yoon Yeong, Wai-Lam Liew, Vikneswaran Murugaiyah, Chee Wei Ang, Hasnah Osman & Soo Choon Tan. (2017) Ethyl nitrobenzoate: A novel scaffold for cholinesterase inhibition. Bioorganic Chemistry 70, pages 27-33.
Crossref
Christiana Franke & Alexander Storch. 2017. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders 947 971 .
Angie A Kehagia. (2016) A neurological perspective on the enhancement debate: Lessons learned from Parkinson’s disease. Journal of Psychopharmacology 30:10, pages 957-966.
Crossref
Anuradha Balasubramanian, Mark Manzano, Tadahisa Teramoto, Rajendra Pilankatta & Radhakrishnan Padmanabhan. (2016) High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Antiviral Research 134, pages 6-16.
Crossref
Rajib Paul & Anupom Borah. (2016) L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. Biochimica et Biophysica Acta (BBA) - General Subjects 1860:9, pages 1989-1997.
Crossref
Lisa von Kleist, Simon Michaelis, Kathrin Bartho, Olivia Graebner, Marén Schlief, Mathias Dreger, Anna K. Schrey, Michael Sefkow, Friedrich Kroll, Hubert Koester & Yan Luo. (2016) Identification of Potential Off-target Toxicity Liabilities of Catechol- O -methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry . Journal of Medicinal Chemistry 59:10, pages 4664-4675.
Crossref
Muhammed Khairujjaman Mazumder, Nivedita Bhattacharjee & Anupom Borah. (2015) Garcinol prevents hyperhomocysteinemia and enhances bioavailability of L-DOPA by inhibiting catechol-O-methyltransferase: an in silico approach. Medicinal Chemistry Research 25:1, pages 116-122.
Crossref
Sabanum Choudhury & Anupom Borah. (2015) Activation of NMDA receptor by elevated homocysteine in chronic liver disease contributes to encephalopathy. Medical Hypotheses 85:1, pages 64-67.
Crossref
Ashish Kumar Kakkar & Neha Dahiya. (2015) Management of Parkinson׳s disease: Current and future pharmacotherapy. European Journal of Pharmacology 750, pages 74-81.
Crossref
Thomas Müller. (2013) Pharmacokinetic Considerations for the Use of Levodopa in the Treatment of Parkinson Disease. Clinical Neuropharmacology 36:3, pages 84-91.
Crossref
Ronald F. Pfeiffer. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease 448 465 .
Aaron LacKamp. 2013. Manual of Geriatric Anesthesia. Manual of Geriatric Anesthesia 379 397 .
Petra Jancova, Pavel Anzenbacher & Eva Anzenbacherova. (2010) PHASE II DRUG METABOLIZING ENZYMES. Biomedical Papers 154:2, pages 103-116.
Crossref
Saviana Di Giovanni, Simona Eleuteri, Katerina E. Paleologou, Guowei Yin, Markus Zweckstetter, Pierre-Alain Carrupt & Hilal A. Lashuel. (2010) Entacapone and Tolcapone, Two Catechol O-Methyltransferase Inhibitors, Block Fibril Formation of α-Synuclein and β-Amyloid and Protect against Amyloid-induced Toxicity. Journal of Biological Chemistry 285:20, pages 14941-14954.
Crossref
Angelo Antonini & Per Odin. (2009) Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism & Related Disorders 15, pages S97-S100.
Crossref
Margherita Canesi, Anna Lena Zecchinelli, Gianni Pezzoli & Angelo Antonini. (2009) Clinical experience of tolcapone in advanced Parkinson’s disease. Neurological Sciences 29:S5, pages 380-382.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.